{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:03Z","timestamp":1747181103647,"version":"3.40.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,16]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists. Hence, we present a protocol for a systematic review and network meta-analysis (NMA) to update the evidence by comparing the efficacy and acceptability of oral immunosuppressive drugs for the treatment of MG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will conduct a systematic review and NMA of all randomized controlled trials evaluating the following oral immunosuppressive drugs for the treatment of MG. Published studies will be searched using the following databases from inception to November 23, 2021: CENTRAL, the CINAHL, MEDLINE, Embase, PsycINFO, Web of Science, and 3 Chinese databases (Chinese Biomedical Literatures Database, CNKI, and Wan Fang database). Assessment of study eligibility and data extraction will be conducted independently by 2 reviewers. The main outcome will be a quantitative MG scoring system. We will conduct Bayesian NMA to synthesize all evidence for each outcome and obtain a comprehensive ranking of all treatments. The quality of the evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The objective of this study was to assess the relative clinical efficacy and acceptability of first-line immunosuppressants for the treatment of MG, using a systematic review and NMA approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In the absence of head-to-head trials comparing therapies, evidence from this NMA of available clinical trials will inform clinicians, patients, and families the risk-benefit profiles of different treatment options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031454","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:02:01Z","timestamp":1671717721000},"page":"e31454","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianying","family":"Chang","sequence":"additional","affiliation":[{"name":"GCP Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanying","family":"Xu","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Scientific Research Office, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianye","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzi","family":"Cui","sequence":"additional","affiliation":[{"name":"GCP Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengfei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China"},{"name":"Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxia","family":"Huang","sequence":"additional","affiliation":[{"name":"Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, Lanzhou University, Lanzhou, Gansu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Health Research, Evidence, and Impact, McMaster University, Hamilton, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-7305","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13503","article-title":"The association of British neurologists\u2019 myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing treatment guidelines for myasthenia gravis","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","article-title":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis","volume":"63","author":"Wang","year":"2019","journal-title":"J Clin Neurosci"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis: a meta-analysis","volume":"18","author":"Ortiz-Salas","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bcp.12150","article-title":"Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data","volume":"77","author":"Kim","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/M15-2521","article-title":"Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials","volume":"164","author":"Trinquart","year":"2016","journal-title":"Ann Intern Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1517\/14656566.2012.705831","article-title":"Treatment strategies for myasthenia gravis: an update","volume":"13","author":"Diaz-Manera","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and treatment of myasthenia gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamapsychiatry.2017.0035","article-title":"Meta-analyses can be credible and useful: a new standard","volume":"74","author":"Ioannidis","year":"2017","journal-title":"JAMA Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:17:09Z","timestamp":1746332229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":38,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031454","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}